Q1 Earnings Forecast for CervoMed Issued By Roth Capital

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for CervoMed in a research report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan forecasts that the company will earn ($0.52) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($2.76) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Several other equities research analysts have also commented on the company. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a research note on Wednesday, December 11th. Roth Mkm upped their price target on CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright lowered CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Chardan Capital upgraded CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, March 13th. Finally, Brookline Capital Management upgraded CervoMed from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, CervoMed presently has a consensus rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Stock Performance

Shares of NASDAQ:CRVO opened at $9.37 on Wednesday. The business has a 50-day moving average of $2.87 and a two-hundred day moving average of $7.88. CervoMed has a 12 month low of $1.80 and a 12 month high of $26.38.

Institutional Trading of CervoMed

Several hedge funds have recently made changes to their positions in CRVO. FMR LLC acquired a new stake in CervoMed in the 3rd quarter valued at approximately $56,000. Barclays PLC increased its position in CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after acquiring an additional 5,919 shares during the period. Virtu Financial LLC acquired a new stake in CervoMed in the 4th quarter valued at approximately $26,000. DRW Securities LLC acquired a new position in shares of CervoMed during the 4th quarter valued at $30,000. Finally, Mariner LLC acquired a new position in shares of CervoMed during the 4th quarter valued at $30,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.